Dirk Reyn is a Pharmacist/MBA with more than 35 years’ experience in the life science industry. He is currently Managing Partner of a new Biotech Venturefund, BioQube Factory Fund (2020).
Dirk has launched 2 blockbuster products at Lilly and JNJ, gained regulatory and crisis management experience, created the CRM business unit and the EU Business Development team at Janssen-Cilag (Johnson & Johnson).
In 2006, Dirk co-founded Movetis NV (Turnhout), a JNJ spin-off for GI assets. As CEO, he was instrumental in building this company from scratch to more than 100 people in 4 years, getting Resolor (a prokinetic) approved In Europe in 2009 for chronic constipation, launched it in four countries with full reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Resolor is today available in more than 20 countries.
Since then Dirk has co-founded Progress Pharma (2013) and did a major BD deal with Nestle/Lipid Therapeutics (2015). In 2016 he co-founded eTheRNA, a spin-off from the University of Brussels with a breakthrough mRNA-based immunotherapy for cancer & infectious diseases and in 2018 co-founded Spectricity, an Imec spin-off. He is also chairman of the board of Across Health (2017) a global leader in CRM communication in the pharma industry.
Since 2013 Dirk is part of the Board of Directors of flanders.bio.
MEET DIRK REYN @ #KFG2020
Dirk Reyn will take part in the final panel debate on September 10th.